Brokerages Set Scholar Rock Holding Corporation (NASDAQ:SRRK) Target Price at $57.71

Scholar Rock Holding Corporation (NASDAQ:SRRK) has been given an average rating of “Buy” by the sixteen brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have given a buy rating and four have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $58.7692.

Several research analysts have commented on SRRK shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $76.00 price objective on shares of Scholar Rock in a research note on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Friday, July 17th. JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $56.00 to $63.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Wedbush reiterated an “outperform” rating and issued a $64.00 price target on shares of Scholar Rock in a report on Friday. Finally, Barclays boosted their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th.

Scholar Rock Price Performance

Scholar Rock stock opened at $58.20 on Thursday. Scholar Rock has a 52-week low of $27.07 and a 52-week high of $58.75. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The firm’s fifty day moving average is $52.10 and its 200 day moving average is $48.56. The company has a market cap of $7.09 billion, a price-to-earnings ratio of -16.87 and a beta of 0.69.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.84). During the same quarter in the prior year, the company earned ($0.98) earnings per share. Sell-side analysts forecast that Scholar Rock will post -3.23 EPS for the current fiscal year.

Insider Transactions at Scholar Rock

In related news, Director Kristina Burow sold 3,053 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total value of $164,068.22. Following the completion of the transaction, the director owned 114,657 shares in the company, valued at $6,161,667.18. This trade represents a 2.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total value of $164,495.64. Following the completion of the transaction, the director owned 27,856 shares of the company’s stock, valued at approximately $1,500,881.28. The trade was a 9.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 17,149 shares of company stock worth $923,108 over the last ninety days. 10.30% of the stock is currently owned by insiders.

Institutional Trading of Scholar Rock

Hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its position in Scholar Rock by 20.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock worth $77,000 after purchasing an additional 242 shares during the period. Values First Advisors Inc. lifted its holdings in shares of Scholar Rock by 1.5% in the 1st quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock valued at $927,000 after buying an additional 286 shares during the period. IFP Advisors Inc boosted its stake in shares of Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after buying an additional 450 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in Scholar Rock by 0.9% during the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock worth $2,209,000 after acquiring an additional 577 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).